These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 15997470)

  • 1. A new strategy for improved secondary screening and lead optimization using high-resolution SPR characterization of compound-target interactions.
    Huber W
    J Mol Recognit; 2005; 18(4):273-81. PubMed ID: 15997470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico fragment-based discovery of DPP-IV S1 pocket binders.
    Rummey C; Nordhoff S; Thiemann M; Metz G
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1405-9. PubMed ID: 16321524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-guided fragment screening for lead discovery.
    Verdonk ML; Hartshorn MJ
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):404-10. PubMed ID: 15338949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance.
    Giannetti AM
    Methods Enzymol; 2011; 493():169-218. PubMed ID: 21371592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fragment-based screening using X-ray crystallography and NMR spectroscopy.
    Jhoti H; Cleasby A; Verdonk M; Williams G
    Curr Opin Chem Biol; 2007 Oct; 11(5):485-93. PubMed ID: 17851109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating surface plasmon resonance biosensor-based interaction kinetic analyses into the lead discovery and optimization process.
    Danielson UH
    Future Med Chem; 2009 Nov; 1(8):1399-414. PubMed ID: 21426056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fragment-based lead discovery: a chemical update.
    Erlanson DA
    Curr Opin Biotechnol; 2006 Dec; 17(6):643-52. PubMed ID: 17084612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovering novel ligands for macromolecules using X-ray crystallographic screening.
    Nienaber VL; Richardson PL; Klighofer V; Bouska JJ; Giranda VL; Greer J
    Nat Biotechnol; 2000 Oct; 18(10):1105-8. PubMed ID: 11017052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NMR techniques for characterization of ligand binding: utility for lead generation and optimization in drug discovery.
    Moore JM
    Biopolymers; 1999; 51(3):221-43. PubMed ID: 10516573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The devil is still in the details--driving early drug discovery forward with biophysical experimental methods.
    Lundqvist T
    Curr Opin Drug Discov Devel; 2005 Jul; 8(4):513-9. PubMed ID: 16022188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New method for fast and accurate binding-site identification and analysis.
    Halgren T
    Chem Biol Drug Des; 2007 Feb; 69(2):146-8. PubMed ID: 17381729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A structure-based strategy to identify new molecular scaffolds targeting the bacterial ribosomal A-site.
    Foloppe N; Chen IJ; Davis B; Hold A; Morley D; Howes R
    Bioorg Med Chem; 2004 Mar; 12(5):935-47. PubMed ID: 14980606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for transient biological interactions as applied to albumin ligands: a new concept for drug discovery.
    Ohlson S; Shoravi S; Fex T; Isaksson R
    Anal Biochem; 2006 Dec; 359(1):120-3. PubMed ID: 17052679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-throughput X-ray crystallography for drug discovery.
    Blundell TL; Patel S
    Curr Opin Pharmacol; 2004 Oct; 4(5):490-6. PubMed ID: 15351354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Label-free primary screening and affinity ranking of fragment libraries using parallel analysis of protein panels.
    Hämäläinen MD; Zhukov A; Ivarsson M; Fex T; Gottfries J; Karlsson R; Björsne M
    J Biomol Screen; 2008 Mar; 13(3):202-9. PubMed ID: 18270366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based development of target-specific compound libraries.
    Orry AJ; Abagyan RA; Cavasotto CN
    Drug Discov Today; 2006 Mar; 11(5-6):261-6. PubMed ID: 16580603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Looking towards label-free biomolecular interaction analysis in a high-throughput format: a review of new surface plasmon resonance technologies.
    Boozer C; Kim G; Cong S; Guan H; Londergan T
    Curr Opin Biotechnol; 2006 Aug; 17(4):400-5. PubMed ID: 16837183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
    Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
    J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico chemical library screening and experimental validation of a novel 9-aminoacridine based lead-inhibitor of human S-adenosylmethionine decarboxylase.
    Brooks WH; McCloskey DE; Daniel KG; Ealick SE; Secrist JA; Waud WR; Pegg AE; Guida WC
    J Chem Inf Model; 2007; 47(5):1897-905. PubMed ID: 17676832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The structural comparison of the bacterial PepX and human DPP-IV reveals sites for the design of inhibitors of PepX activity.
    Rigolet P; Xi XG; Rety S; Chich JF
    FEBS J; 2005 Apr; 272(8):2050-9. PubMed ID: 15819895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.